Biocon to sell branded formulations business to Eris Lifesciences for $150 mn

The deal, which is expected to close by April 15, 2024, includes the acquisition of insulin brands Basalog and Insugen which Eris said will help its diabetes treatment franchise reach 10 billion rupees in revenue, without specifying a timeline.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news